Aficamten

Phase 3

Cytokinetics, Incorporated (CYTK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

View Full Landscape

Drug Information

Target Indication

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Clinical Trial

NCT06081894

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/12/2026

Myqorzo

Myqorzo is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CYTK

Cytokinetics, Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Omecamtiv MecarbilPhase 3

Heart Failure With Reduced Ejection Fraction

Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Standard of CarePhase 3

Heart Failure

Omecamtiv Mecarbil (OM)Phase 3

Heart Failure

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts